EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Post-induction serum vedolizumab levels are not associated with better maintenance outcomes in patients with Crohn’s disease

Jagoda Pokryszka iD, Christian Primas, Michael Stadlmann, Nathalie Gerold, Cornelia Lichtenberger, Sieglinde Reinisch, Gottfried Novacek, Walter Reinisch

Zeitschrift für Gastroenterologie · 01.02.2026 · 64 (02) · 157-167

DOI: 10.1055/a-2744-5136 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Zeitschrift für Gastroenterologie, erschienen am 01.02.2026. Verfasst von Jagoda Pokryszka und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Wien, Austria. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Crohn Disease, Gastrointestinal Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Results on exposure-efficacy relationships for vedolizumab in patients with Crohn’s disease are contentious. Our study aimed at exploring the relationship between vedolizumab serum concentrations measured during induction and maintenance and treatment outcomes in Crohn’s disease patients in a real-world setting. Crohn’s disease patients treated with vedolizumab between January 2014 and July 2022 at our tertiary care centre were included. Serum vedolizumab concentrations were measured on at least one of the following time points: week 2, 6, 12, 26, and/or 52. Treatment efficacy was evaluated at weeks 12, 26 and 52 as clinical remission based on patients reported outcomes, faecal calprotectin and C-reactive protein remission. In total, 58 patients (55.2% females) were included. At baseline, active disease, defined either by increased faecal calprotectin, C-reactive protein or patients reported outcomes, was observed in 53 patients (91.4%). Week 12 vedolizumab serum levels were higher in clinical remitters versus non-remitters at weeks 12 and 52 (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedCrohn DiseaseGastrointestinal AgentsHumansFemaleTreatment OutcomeMaleAdultMiddle AgedRemission InductionRetrospective Studies

Substanzen

Antibodies, Monoclonal, HumanizedvedolizumabGastrointestinal Agents

Autor:innen und Institutionen

  • Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Wien, Austria.
  • Magen-Darm-Gesundheitszentrum, Mödling, Austria.

ORCID-Profile: Jagoda Pokryszka

Zitieren

APA

Pokryszka, J., Primas, C., Stadlmann, M., Gerold, N., Lichtenberger, C., Reinisch, S., Novacek, G., & Reinisch, W. (2026). Post-induction serum vedolizumab levels are not associated with better maintenance outcomes in patients with Crohn’s disease. Zeitschrift für Gastroenterologie, 64(02), 157-167. https://doi.org/10.1055/a-2744-5136

Vancouver

Pokryszka J, Primas C, Stadlmann M, Gerold N, Lichtenberger C, Reinisch S, et al. Post-induction serum vedolizumab levels are not associated with better maintenance outcomes in patients with Crohn’s disease. Zeitschrift für Gastroenterologie. 2026;64(02):157-167. doi:10.1055/a-2744-5136

BibTeX
@article{Pokryszka2026,
  author = {Pokryszka, Jagoda and Primas, Christian and Stadlmann, Michael and Gerold, Nathalie and Lichtenberger, Cornelia and Reinisch, Sieglinde and Novacek, Gottfried and Reinisch, Walter},
  title = {Post-induction serum vedolizumab levels are not associated with better maintenance outcomes in patients with Crohn’s disease},
  journal = {Zeitschrift für Gastroenterologie},
  year = {2026},
  volume = {64},
  number = {02},
  pages = {157--167},
  doi = {10.1055/a-2744-5136}
}
Kostenlos starten →